Functional, Clinical, and Sociodemographic Variables Associated with Risk of In-Hospital Mortality by COVID-19 in People over 80 Years Old

I. Rodríguez-Sánchez1, M. Redondo-Martín1, L. Furonés-Fernández1, M. Méndez-Hinojosa1, Á. Chen-Chim1, R. Saavedra-Palacios1, P. Gil-Gregorio1,2

1. Department of Geriatric Medicine. Hospital Universitario Clínico San Carlos, Madrid, Spain; 2. Fundación para la investigación biomédica del Hospital Clínico San Carlos, Madrid, Spain

Introduction

OBJECTIVES: The objective is to assess the role of functional, clinical, and analytic parameters in predicting mortality in older patients hospitalized due to COVID-19.

DESIGN: Cohort study with a mean follow-up of 12.8 days.

SETTING: Public university hospital (Madrid, Spain).

PARTICIPANTS: 499 patients 80 and above consecutively admitted to a Spanish public university hospital between 4 March 2020 and 16 May 2020.

MEASUREMENTS: Mortality was the main outcome. Data of sociodemographic variables (age, sex, living), comorbidities, polypharmacy, functional status, date of hospital admission and length of stay was recorded. Clinical symptoms, laboratory and X-ray findings were collected at time of admission. For multivariable analysis, logistic regressions were performed to identify risk factors for death.

RESULTS: Mean age was 86.7±4.4 with 37% of death. Mortality was associated with male gender [odds ratio (OR) 1.50; 95% confidence interval (CI) 1.01-2.24], with a 5-points increase on Barthel Index [OR 1.01 (95% CI 1.00-1.02)], higher Charlson Index score [OR 1.13 (95% CI 1.02-1.26)] and comorbidities [OR 1.28 (95% CI 1.06-1.53)], hyperpolipharmacy [OR 2.00 (95% CI 1.04-3.82)], unilateral pneumonia [OR 1.83 (95% CI 1.01-3.30)], higher levels of C-reactive protein [OR 1.09 (95% CI 1.06-1.12)] and creatine [OR 1.48 (95% CI 1.15-1.89)]. Higher oxygen levels were a protective factor [OR 0.92 (95% CI 0.89-0.95)].

CONCLUSIONS: Functional status, being male, a higher burden of comorbidities, hyperpolipharmacy, unilateral pneumonia and some laboratory parameters predict in-hospital mortality in this older population. The knowledge of these mortality risk factors should be used to improve the survival of older hospitalized patients.

Key words: SARS-Cov-2, functional status, blood parameters, mortality, older people.

Methods

Study design and participants

We performed a cohort monocentric study at a public 861-beds University Hospital in Madrid (Spain), including all patients aged 80 years-old and older consecutively admitted since 4 March 2020 to 16 May 2020 during the first wave of pandemic. In all of them, diagnosis of infection for SARS-
CoV-2 was confirmed at admission through a positive result on polymerase chain reaction test of a nasopharyngeal sample. The initial sample size was 538. Participants with no information on Barthel Index, usual medication, and levels of C-reactive protein (CRP), nor renal function (creatinine) were excluded. Thus, the final sample for analysis was composed by 499 subjects (Figure 1). There were no differences according to age, gender and comorbidities between those excluded and the final sample.

### Study variables

#### Outcomes

Hospital mortality was the main outcome of this study. Patients were followed until hospital discharge or in-hospital death, whichever was first.

#### Predictors and adjusting variables

Sociodemographic variables: data on age, gender, and living (community-dwelling or nursing homes) were collected from clinical records.

Functional status: The functional status was based on Barthel Index obtained from both clinical records or primary health care records.

Comorbidities and usual medication: information on comorbidities before admission (hypertension, diabetes, chronic obstructive pulmonary disease, chronic heart failure, ischemic cardiopathy, dementia, chronic renal failure, cerebrovascular disease, cancer, and tuberculosis) was also obtained. Stemming from this information we calculated the Charlson index and the Cumulative Illness Rating Scale-Geriatric (CIRS-G). Polypharmacy was assessed according to the number of usual medication. Patients were classified in 3 groups: without polypharmacy (<5 drugs), polypharmacy (5-9 drugs), and hyperpolipharmacy (≥10).

Clinical manifestations: symptoms at admission (fever, cough, dyspnea, oxygen saturation, anorexia, myalgias or arthralgias, headache, digestive symptoms, dizziness, and ageusia/anosmia) were also collected.

Laboratory and imaging findings: data on initial laboratory testing was defined as test results obtained within the first 24 hours at the Emergency department (ED). The diagnosis of pneumonia on chest X-ray at admission on ED was also

---

### Table 1. Sociodemographic factors, functional status, chronic morbidities and hospital mortality in old patients hospitalized by COVID-19 [n=499]

| Characteristics                              | Total       | Recovered (n=319; 63%) | Death (n=187; 37%) | P value |
|----------------------------------------------|-------------|------------------------|--------------------|---------|
| Age; mean (SD)                               | 86.7 (4.4)  | 86.5 (4.2)             | 87.1 (4.7)         | 0.06    |
| Male; n (%)                                  | 245 (49.1)  | 143 (45.4)             | 102 (55.4)         | 0.03    |
| Length stay; mean (SD)                       | 12.8 (10.6) | 15.1 (10.2)            | 8.8 (10.2)         | 0.98    |
| Living; n(%)                                 |             |                        |                    | 0.06    |
| Community-dwelling                           | 421 (84.4)  | 273 (86.7)             | 148 (80.4)         |         |
| Nursing home                                 | 78 (15.6)   | 42 (13.3)              | 36 (19.6)          |         |
| Barthel Index; mean (SD)                     | 78.1 (27.5) | 80.5 (25.7)            | 73.8 (29.9)        | 0.02    |
| Hypertension; n (%)                          | 406 (81.4)  | 252 (80.0)             | 154 (83.7)         | 0.31    |
| Diabetes; n (%)                              | 146 (29.3)  | 81 (25.7)              | 65 (36.3)          | 0.02    |
| Chronic obstructive respiratory disease; n (%)| 90 (18.0)   | 54 (17.1)              | 36 (19.6)          | 0.50    |
| Tuberculosis; n (%)                          | 21 (4.2)    | 13 (4.1)               | 8 (4.4)            | 0.91    |
| Heart failure; n (%)                         | 165 (33.1)  | 101 (32.1)             | 64 (34.8)          | 0.53    |
| Ischemic cardiopathy; n (%)                  | 82 (16.4)   | 45 (14.3)              | 37 (20.1)          | 0.09    |
| Dementia; n (%)                              | 124 (24.9)  | 67 (21.3)              | 57 (31.0)          | 0.02    |
| Chronic renal failure; n (%)                 | 100 (20.0)  | 58 (18.4)              | 42 (22.8)          | 0.24    |
| Cerebrovascular disease; n (%)               | 57 (11.4)   | 28 (8.9)               | 29 (15.8)          | 0.02    |
| Cancer; n (%)                                | 102 (20.4)  | 62 (19.7)              | 40 (21.7)          | 0.58    |
| CIRSG score; mean (SD)                       | 11.3 (5.6)  | 10.9 (5.3)             | 11.9 (6.1)         | 0.04    |
| Charlson score; mean (SD)                    | 5.9 (1.9)   | 5.7 (1.6)              | 6.3 (2.3)          | <0.001  |
| Polypharmacy; n (%)                          |             |                        |                    | 0.03    |
| No (<5)                                      | 136 (27.3)  | 98 (31.1)              | 38 (20.7)          |         |
| Yes (5-9)                                    | 200 (40.1)  | 124 (39.4)             | 76 (41.3)          |         |
| Hyperpolipharmacy (≥10)                      | 163 (32.7)  | 93 (29.5)              | 70 (38.0)          |         |

SD: Standard Deviation; %: Percentage; *p-values for differences in means were obtained from ANOVA or Kruskal Wallis, as appropriate; while p-values for differences in proportions were obtained from chi squared tests.
Specific treatment for COVID-19: the use of treatment against COVID (azithromycin, hydroxychloroquine, lopinavir/ritonavir, corticosteroids, interferon, and immune modulator) was additionally reported.

**Statistical analysis**

Quantitative variables were expressed as means and standard deviations and qualitative variables as percentages. Differences in the quantitative variables between those who died and those who did not were assessed using the ANOVA or Kruskall Wallis; differences in percentages were assessed using the chi squared test.

To assess the association between hospital mortality and each studied variable, we used multivariate logistic regression (results presented as odds ratios and their confidence intervals). With this purpose, 5 models were fitted. Model 1 was adjusted for sex and age. Next, the potential mediation of function (Barthel index) was assessed by adding to model 1 (model 2). Then, the score on Cumulative Illness Rating Scale- Geriatrics (CIRS-G) was added to the previous model (model 3). Further, a fourth model was created adjusted additionally for the presence of polypharmacy. Finally, model 5 was defined as model 4 plus adjusted for C-reactive protein.

The level of significance was set at p value < 0.05 or less. Statistical analyses were performed with STATA (version 14.0; Stata Corp., College Station).

**Results**

**Differences between groups**

**Characteristics of study participants**

Population characteristics are described in Table 1. 499 participants with a mean age of 86.7 ± 4.4 (ranging from 80 to 106 years old) with a mean length stay of 12.8 days (± 10.6) were included in this study. In those who survived, the mean length stay was 15.1(± 10.3) days versus 8.7 (± 10.1) in the deceased group (p=0.86).

The hospital mortality in our study was 37%. Compared to the 319 survivors, the 187 non-survivors were predominantly men; with lower Barthel Index score; higher score in comorbidities indices (both CIRS-G and Charlson index); higher prevalence of diabetes, dementia, and cerebrovascular disease; and higher rates of hyperpolypharmacy, being all these differences statistically significant (table 1).

**Clinical Presentation, Laboratory and Imaging Findings**

Table 2 summarizes the initial symptoms, laboratory and imaging findings, and treatment received. According to clinical presentation, differences between the 2 groups were statistically significant for fever (73.4% non-survivors vs 62.9% survivors; P=0.02), dyspnea (64.7 non-survivors vs 49.8% survivors; P=0.001) and mean oxygen saturation (88.7% ± 8.5 non-survivors vs 93.3% ± 5.0; P=<0.001).

Regarding to laboratory findings (Table 2) compared to those who survived, people who died during hospitalization had higher rates of hypo or hypernatremia and lymphopenia. Additionally, an increase on inflammatory biomarkers was observed in non-survivors in CRP, procalcitonin, ferritin, and d-dimer, all of them with p-value <0.001. Participants who died had also an increased glucose level and worse renal function.

According to chest X-ray, a normal image was more frequent in those who survived.

**Treatment**

Different treatment options related to COVID-19 were administrated during hospitalization (Table 2). The most used treatment regimen were hydroxychloroquine (65.9%), corticosteroids (28.5%), lopinavir/ritonavir (26.1%), and azithromycin (25.5%). Interferon and other immune modulator were rarely used. Compared to survivors, non-survivors received higher rates of azithromycin (22.2% vs 31%, respectively; p=0.03) and lower rates of hydroxychloroquine (71.4% vs 56.5%, respectively; p=0.001).

**Risk assessment of death**

**Sociodemographic variables, functional status, comorbidities and polypharmacy**

We assessed the risk factors associated to death through five models. Table 3 shows that, compared to female, being male was associated with a higher risk of hospital mortality due to covid-19, with an OR 1.50 (95%CI 1.01-2.24, p=0.05). Additionally, each 5-points increase on Barthel Index [OR 1.01 (95%CI 1.00-1.02, p=0.03)], as well as a higher Charlson Index score [OR 1.13 (95%CI 1.02-1.26, p=0.03)] and a higher number of comorbidities [OR 1.28 (95%CI 1.06-1.53, p=0.01)]
Table 2. Symptoms, laboratory findings, imaging, treatment, and hospital mortality in old patients hospitalized by COVID-19 [n=499]

| Initial symptoms                      | Total     | Recovered (n=319; 63%) | Death (n=187; 37%) | P value |
|---------------------------------------|-----------|------------------------|--------------------|---------|
| Fever; n (%)                          | 333 (66.7)| 198 (62.9)             | 135 (73.4)         | 0.02    |
| Cough; n (%)                          | 283 (56.7)| 174 (55.2)             | 109 (59.2)         | 0.38    |
| Dyspnea; n (%)                        | 276 (55.3)| 157 (49.8)             | 119 (64.7)         | 0.001   |
| Saturation (%) and mean (SD)          | 91.6 (6.8)| 93.3 (5.0)             | 88.7 (8.5)         | <0.001  |
| Anorexia; n (%)                       | 106 (21.2)| 68 (21.6)              | 38 (20.7)          | 0.81    |
| Myalgias/arthritis; n (%)             | 72 (14.4) | 52 (16.5)              | 20 (10.9)          | 0.08    |
| Headache; n (%)                       | 23 (4.6)  | 19 (6.0)               | 4 (2.2)            | 0.05    |
| Digestive symptoms; n (%)             | 115 (23.1)| 81 (25.7)              | 34 (18.5)          | 0.06    |
| Dizziness; n (%)                      | 34 (6.8)  | 19 (6.0)               | 15 (8.2)           | 0.36    |
| Ageusia/anosmia; n (%)                | 13 (2.6)  | 10 (3.2)               | 3 (1.6)            | 0.30    |

| Laboratory findings                   | Total     | Recovered (n=319; 63%) | Death (n=187; 37%) | P value |
|---------------------------------------|-----------|------------------------|--------------------|---------|
| Sodium; n (%)                         | 352 (70.5)| 236 (74.9)             | 116 (63.0)         | 0.004   |
| Normonatremia (135-145 mmol/L)        | 125 (25.1)| 71 (22.5)              | 54 (29.4)          |         |
| Hyponatremia (<135 mmol/L)            | 22 (4.4)  | 8 (2.5)                | 14 (7.6)           |         |
| Lymphocytes (U/UL); mean (SD)         | 1,008.6 (1,739.9)| 1,068.0 (2,061.2) | 903.8 (931.4) | <0.001 |
| Platelets (U/UL); mean (SD)           | 192,803.7 (91,952.6)| 201,243.6 (98,530.8)| 178,262.5 (77,596.7) | <0.001 |
| C-reactive protein (mg/dL); mean (SD) | 9.4 (8.0)| 7.5 (6.5)              | 12.6 (9.3)         | <0.001  |
| Procalcitonin (ng/mL); mean (SD)      | 0.9 (6.7)| 0.4 (1.7)              | 1.9 (11.1)         | <0.001  |
| Proteins (g/dL); mean (SD)            | 5.6 (1.5)| 5.5 (1.7)              | 5.8 (1.3)          | 0.05    |
| Albumin (g/dL); mean (SD)             | 3.0 (0.9)| 2.9 (1.0)              | 3.1 (0.7)          | 0.03    |
| Cholesterol (mg/dL); mean (SD)        | 128.6 (49.1)| 129.8 (50.8)         | 126.0 (45.7)       | 0.40    |
| Creatine (mg/dL); mean (SD)           | 1.26 (1.05)| 1.1 (0.7)             | 1.5 (1.4)          | <0.001  |
| Ferritin (ng/mL); mean (SD)           | 797.3 (2,230.2)| 610.4 (847.4)       | 1,198.5 (3,699.9) | <0.001  |
| D-dimer (ng/mL); mean (SD)            | 3,406.5 (9,979.1)| 2,399.6 (5,364.3)   | 5,470.7 (15,323.6) | <0.001  |
| Glucose (mg/dL); mean (SD)            | 132.2 (71.3)| 128.7 (76.1)         | 138.0 (62.4)       | 0.002   |

| Lung imaging                          | Total     | Recovered (n=319; 63%) | Death (n=187; 37%) | P value |
|---------------------------------------|-----------|------------------------|--------------------|---------|
| No pneumonia; n (%)                   | 90 (18.0)| 66 (20.7)              | 25 (13.4)          | 0.04    |
| Unilateral pneumonia; n (%)           | 198 (39.7)| 115 (36.1)            | 86 (46.0)          |         |
| Bilateral pneumonia; n (%)            | 211 (42.3)| 138 (43.3)            | 76 (40.6)          |         |

| Treatment                              | Total     | Recovered (n=319; 63%) | Death (n=187; 37%) | P value |
|---------------------------------------|-----------|------------------------|--------------------|---------|
| Azithromycin; n (%)                   | 127 (25.5)| 70 (22.2)              | 57 (31.0)          | 0.03    |
| Hydroxychloroquine; n (%)             | 329 (65.9)| 225 (71.4)             | 104 (56.5)         | 0.001   |
| Lopinavir/ ritonavir; n (%)            | 130 (26.1)| 77 (24.4)              | 53 (28.8)          | 0.28    |
| Corticosteroids; n (%)                | 142 (28.5)| 87 (27.6)              | 55 (30.0)          | 0.58    |
| Interferon; n (%)                     | 27 (5.4)  | 7 (2.2)                | 20 (10.9)          | <0.001  |
| Immune modulator; n (%)               | 5 (1.0)   | 4 (1.3)                | 1 (0.5)            | 0.43    |

SD: Standard Deviation; %: Percentage. *p-values for differences in means were obtained from ANOVA or Kruskall Wallis, as appropriate; while p-values for differences in proportions were obtained from chi squared tests.
were related to a higher likelihood of mortality. Participants diagnosed by cerebrovascular disease were at higher risk of dying, compared to those who did not [OR 2.08 (95% CI 1.12-3.87, p=0.02)]. Hyperpolypharmacy, but not polypharmacy was also linked to a higher rate of hospital mortality [OR 2.00 (95% CI 1.12-3.87, p=0.02)]. Hyperpolyphtomy, but not polypharmacy was related to a higher likelihood of mortality. Participants diagnosed by cerebrovascular disease were at higher risk of dying, compared to those who did not [OR 2.08 (95% CI 1.12-3.87, p=0.02)]. Hyperpolypharmacy, but not polypharmacy was also linked to a higher rate of hospital mortality [OR 2.00 (95% CI 1.12-3.87, p=0.02)].

No association was observed between any type of treatment and risk of mortality.

Discussion

Our study showed that being male, having a worse functional status, a greater burden due to comorbidities, hyperpolyphtomy, being diagnosed of unilateral pneumonia, and having high levels of creatine and CRP at admission are independent risk factors for hospital mortality for people older than 80 with COVID-19. Additionally, higher levels of blood oxygen have a protective role for mortality in these patients.

In this analysis, male gender has been demonstrated to be a risk factor of mortality, being consistent with previous literature. A study published in 2020 reported that the angiotensin-converting enzyme 2 (ACE2) enzyme may be

Clinical Presentation, Laboratory and Imaging Findings

Higher oxygen levels were protective factor of mortality [OR 0.92 (95%CI 0.89-0.95, p<0.001)], compared to lower rates of oxygen. Moreover, compared to those with no pneumonia, only unilateral pneumonia showed an association with hospital mortality [OR 1.83 (95%CI 1.01-3.30, p=0.05)], whereas no relationship was observed with bilateral pneumonia.

Regarding to laboratory parameters, individuals with higher levels of CRP [OR 1.09 (95%CI 1.06-1.12, p<0.001)] and creatine [OR 1.48 (95%CI 1.15-1.89, p=0.002)] were at higher risk of mortality, compared to those with lower values. Ferritin, procalcitonin, albumin, protein, cholesterol, and d-dimer levels were excluded from analysis due to missing values.

No association was observed between place of living and risk of mortality.

Table 3. Risk factors associated to in-hospital mortality in older people with covid-19 (n=499)

| Variable                               | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | Model 4 OR (95% CI) | Model 5 OR (95% CI) |
|----------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Gender (male)                          | 1.53 (1.06-2.2)     | 1.62 (1.11-2.35)    | 1.58 (1.08-2.30)    | 1.63 (1.12-2.38)    | 1.50 (1.01-2.24)    |
| Living (nursing home)                  | 1.54 (0.92-2.59)    | 1.21 (0.68-2.14)    | 1.23 (0.69-2.18)    | 1.21 (0.68-2.15)    | 1.31 (0.72-2.39)    |
| Barthel Index                          | 1.01 (1.00-1.02)    | -                   | 1.01 (1.00-1.02)    | 1.01 (1.00-1.02)    | 1.01 (1.00-1.02)    |
| Charlson Index                         | 1.15 (1.04-1.27)    | 1.1 (1.03-1.26)     | 1.14 (1.02-1.26)    | 1.13 (1.02-1.26)    | 1.13 (1.02-1.26)    |
| Comorbidities                          | 1.22 (1.07-1.38)    | 1.19 (1.04-1.35)    | 1.26 (1.05-1.49)    | 1.24 (1.04-1.47)    | 1.28 (1.06-1.53)    |
| Dementia                               | 1.66 (1.09-2.53)    | 1.37 (0.85-2.22)    | 1.36 (0.84-2.20)    | 1.32 (0.81-2.14)    | 0.27 (0.89-2.49)    |
| Cerbrovascular disease                 | 1.93 (1.10-3.38)    | 1.77 (1.00-3.12)    | 1.70 (0.94-3.06)    | 1.73 (0.96-3.15)    | 2.08 (1.12-3.87)    |
| Diabetes mellitus                      | 1.54 (1.03-2.29)    | 1.59 (1.07-2.37)    | 1.55 (1.03-2.34)    | 1.50 (0.99-2.27)    | 0.50 (0.90-2.16)    |
| Polypharmacy                           | <5                  | Ref.                | Ref.                | Ref.                | Ref.                |
|                                      | 5-9                 | 1.54 (0.96-2.48)    | 1.52 (0.94-2.45)    | 1.60 (0.96-2.67)    | 1.61 (0.95-2.66)    |
|                                      | ≥ 10                | 1.95 (1.19-3.18)    | 1.84 (1.12-3.02)    | 2.03 (1.03-3.74)    | 2.04 (1.11-3.75)    |
| Symptoms                               |                     |                     |                     |                     |                     |
| Fever                                 | 1.63 (1.09-2.43)    | 1.68 (1.12-2.52)    | 1.69 (1.13-2.54)    | 1.69 (1.12-2.55)    | 1.36 (0.89-2.10)    |
| Dyspnea                               | 1.86 (1.27-2.71)    | 1.78 (1.22-2.60)    | 1.77 (1.21-2.59)    | 1.76 (1.20-2.58)    | 1.46 (0.97-2.18)    |
| Oxygen level                           | 0.90 (0.87-0.93)    | <0.001             | 0.90 (0.86-0.93)    | <0.001             | 0.90 (0.87-0.93)    |
| Radiology                              |                     |                     |                     |                     |                     |
| No pneumonia                           |                     |                     |                     |                     |                     |
| Unilateral pneumonia                   | 1.86 (1.08-3.20)    | 2.01 (1.18-3.59)    | 2.21 (1.25-3.89)    | 2.18 (1.29-4.03)    | 1.83 (1.01-3.30)    |
| Bilateral pneumonia                    | 1.32 (0.77-2.29)    | 0.31                | 1.48 (0.85-2.59)    | 1.53 (0.87-2.68)    | 1.51 (0.86-2.65)    |
| Laboratory parameters                  |                     |                     |                     |                     |                     |
| Sodium (mmol/L)                        |                     |                     |                     |                     |                     |
| Normal values (135-145)                |                     |                     |                     |                     |                     |
| Hypoaemia                              | 1.58 (1.04-2.41)    | 1.61 (1.06-2.47)    | 1.61 (1.05-2.46)    | 1.56 (1.01-2.39)    | 1.36 (0.86-2.11)    |
| Hyperaemia                             | 3.29 (1.33-8.18)    | 2.60 (1.01-6.65)    | 2.57 (1.00-6.58)    | 2.41 (0.93-6.25)    | 2.16 (0.81-5.79)    |
| C-reactive protein (mg/dL.)            | 1.09 (1.06-1.11)    | <0.001             | 1.09 (1.06-1.12)    | <0.001             | 1.09 (1.06-1.12)    |
| Creatine (mg/dL.)                      | 1.58 (1.25-2.00)    | <0.001             | 1.58 (1.25-1.99)    | <0.001             | 1.57 (1.24-1.99)    |
| Lymphocytes (U/mL)                     | 1.00 (0.99-1.00)    | 0.43                | 1.00 (0.99-1.00)    | 0.37                | 1.00 (0.99-1.00)    |

OR: Odds Ratio. CI: Confidence interval. Model 1: Adjusted for sex and age. Further adjusted for the corresponding independent variables [Model 2: As model 1 and additionally adjusted for Barthel Index; model 3: As model 2 and additionally adjusted for Cumulative Illness Rating Scale-Geriatrics (CIRS-G); model 4: As model 3 and additional adjusted for number of usual medications; model 5: As model 4 and additionally adjusted for C-reactive protein (mg/dL)].
the host receptor for SARS-COV2, and this protein has a high expression in the lung tissues of men (15). Moreover, some previous studies have proposed a relation between that susceptibility and a X-linked inheritance, since both the androgen receptor gene and ACE2 genes are located at chromosome X (16, 17), playing an important role in the innate and adaptive immunity of female patients.

We confirm the role of functional status in predicting mortality in this very old population. According to previous studies (3, 18–20), functional status was a strong predictor of risk of death in very old people with COVID-19 disease, showing an increase of 1% in the risk of mortality by each 5-points decrease. Compare to a previous Spanish study (3), although this percentage is lower than the one they observed (a mean increase of 10-15% in the risk of death for each decrease of 5 points in Barthel Index). This lower effect of function can be explained by the higher age of the population in our study, taking into account that as people get older, the burden of age among mortality is the highest (21).

It is widely known the role of polypharmacy as a risk factor for adverse outcomes in older population (22–25), although this association is controversial in patients with COVID-19. In the study of Laosa et al (3), they did not find a role for polypharmacy (defined by taking ≥5) in the full-adjusted model. However, similarly, in our study we only found an association with the risk of death when the number of usual drugs were 10 or higher, but not in those taking 5-10 drugs. These findings suggest that polypharmacy is a risk factor in these populations when it is remarkably high.

Severe COVID-19 disease is defined as dyspnea or blood oxygen saturation of 93% or less, among other clinical and radiological characteristics (4). As we described before, fever, dyspnea and desaturation were the most common symptoms in our sample. The three of them were also associated with increased risk of death, acting only the oxygen level as an independent risk factor of death. In other studies, the prevalence of cardinal symptoms such as fever and dyspnea appear to be similar in older patients (19). Desaturation and tachypnea have particularly been identified as common risk factors for advanced respiratory support and mortality (26). In our study patients with unilateral pneumonia were at higher risk of mortality compared to those without pneumonia but, contrary to what was expected, having bilateral pneumonia did not increase the risk of death. This finding must be taken with caution, as we only included the first chest radiography performed at admission. It is not uncommon for patients with COVID-19 disease to worsen in the following days from admission, developing an inflammatory response with the subsequent progression of the baseline infiltrates. In addition to it, the extension of the pulmonary infiltrates was not taken into account. Thus, mild, or dubious infiltrates in both lung fields were also named as bilateral pneumonia, even though the severity of those infiltrates were low.

When analyzing some biochemical parameters, higher levels of C-reactive protein and creatine could be considered risk factors of mortality, as it has been demonstrated in previous studies (26, 27). These findings show up the association between an excessive systemic inflammatory response and a higher risk of poor outcomes, as well as the risk of mortality that lower estimated glomerular filtration rate involves. In fact, there is evidence in previous studies that chronic kidney disease contributes to death and it is associated with disease severity (28, 29). Hyponatremia and hypernatremia were also associated with a higher risk of death in almost all of our models. Dysnatremia has been related to a poor prognosis in hospitalized patients, specifically in those with community-acquired pneumonia (30–32). Additionally, a retrospective study conducted on 4664 patients aged 17 and older with COVID-19 infection (HOPE-COVID-19 study) (33), also demonstrated that both hyponatremia and hypernatremia were independently associated to in-hospital mortality.

Our study has several strengths and limitations. Among the first ones, this present work is unique by focusing on the oldest-old patients with a large sample size (499 subjects) composed by consecutively admitted, thus limiting the potential for selection bias. In addition, we enrolled a heterogeneous group with many different features and clinical presentations, allowing us to identify a variety of risk factors for severe COVID-19 in this population.

On the other hand, one potential limitation of our study is related to the period of time in which it was performed. Between the months of March and May, 2020, the Spanish health care system was close to collapse and we cannot discard that other very old patients with severe disease were not sent to an emergency room/hospital, including those with mild symptoms fit enough to home isolation without medical care or those with very poor prognosis living in nursing homes to whom only palliative care could be offered. Thus, some results in our study may be biased.

In conclusion, the current study showed that gender, functional status, and some clinical, laboratory, and radiology variables play an important role as an independent risk factors for hospital mortality in patients over 80 with COVID-19, providing useful information for an early identification of higher risk patients. The knowledge accumulated so far on how to treat hospitalized patients with COVID-19 should be used to improve survival of the most vulnerable individuals.

Declaration of conflict of interest: None.

Declaration of sources of funding: Fundación Fernández-Cruz.

Author Contributions: Study concept and design: all authors. Data collection: MRM, LFF, MMH, ACC, RSP. Statistical analyses: IRS. Draft of the manuscript: IRS, MRM, LFF, MMH, ACC, RSP. Full access to all of the data in the study and responsibility for the integrity of the data and the accuracy of the data analysis: IRS. Study supervision: PGG. All authors reviewed the manuscript for important intellectual content and approved the final version.

Ethical standards: We consciously assure that for the manuscript «Functional, clinical, and sociodemographic risk variables of hospital mortality by COVID-19 in people over 80 years old” for the following is fulfilled: This manuscript is the authors’ own original work, which has not been previously published elsewhere, whole or in part. The paper is not currently being considered for publication elsewhere. If it will be accepted, the paper will not be published elsewhere in the same form without the written consent of the copyright holder. All sources and previous publications used are properly cited, with proper reference. All co-authors are included on the paper, and all of them have approved the final version of the manuscript and have agreed that the work is ready for submission. All authors will take public responsibility for the manuscript content. All authors meet the criteria for authorship stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
References

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470–473.

2. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data Available at: https://covid19.who.int/. Accessed May 6, 2021.

3. Laosa O, Pedraza L, Álvarez-Bustos A, Carnicero JA, Rodríguez-Artalejo F, Rodríguez-Mañas L. Rapid Assessment at Hospital Admission of Mortality Risk From COVID-19: The Role of Functional Status. J Am Med Dir Assoc 2020;21:1798-1802. e2.

4. Vrillon A, Hourregue C, Azar J, Grosset L, Boutelier A, Tan S, Roger M, Mourvan V, Mouly S, Sène D, François V, Damarguer J, Paquet C. COVID-19 in Older Adults: A Series of 76 Patients Aged 85 Years and Older with COVID-19. J Am Geriatr Soc 2020;68:2735-2743.

5. COVID-19 strategy update - 14 April 2020 Available at: https://www.who.int/publications/i/item/covid-19-strategy-update--14-april-2020. Accessed May 6, 2021.

6. Redondo-Bravo L, Moros MS, Sanchez EVM, et al. The first wave of the COVID-19 pandemic in Spain. Characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Eurosurveillance 2020;25:2001431.

7. Defunciones por covid-19 virus identificado y virus no identificado (sospechoso), mes de defunción, sexo y edad Available at: https://ine.es/jaxi/Tabla.htm?path=/t15/p417/covid/0&file=01001.px&L=0. Accessed May 6, 2021.

8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

9. Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80:639–645.

10. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020;80:e14–e18.

11. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Assoc 2020;323:2052–2059.

12. Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, Lin S. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 2020;92:2152–2158.

13. Hoogendijk EO, Romero L, Sánchez-Jurado PM, Flores Ruano T, Viña J, Rodríguez-Mañas L, Abizanda P. A New Functional Classification Based on Frailty and Disability Stratifies the Risk for Mortality Among Older Adults: The FRADEA Study. J Am Med Dir Assoc 2019;20:1105–1110.

14. Hewitt J, Carter B, Vlček-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health 2020;5:e444–e451.

15. Li R, Qiao S, Zhang G. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. J Infect 2020;80:469–496.

16. Wambier CG, Goren A, Vaño-Galván S, Ramos PM, Ossimetha A, Nau G, Herrera S, McCoy J. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res 2020;81:771–776.

17. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhu, China: a descriptive study. Lancet 2020;395:507–513.

18. Alsahbah M, Besikson L, Brown B, et al. Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study. Age Ageing 2021;50:617–630.

19. Knopp P, Miles A, Webb TE, Mcloughlin BC, Mannan I, Raja N, Wan B, Davis D. Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality. Eur Geriatr Med 2020;11:1089–1094.

20. Blommaard LC, van der Linden CMJ, van der Bol JM, et al. Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in the Netherlands: the COVID-OLD study. Age Ageing. 2021. doi:10.1093/ageing/afab018.

21. Sourial N, Bergman H, Karunanithan S, Wolfson C, Payette H, Gutierrez-Robledo LM, Bélard F, Fletcher JD, Gurulkint J. Implementing frailty into clinical practice: A cautionary tale. Journals Gerontol - Ser A Biol Sci Med Sci 2013;68:1505–1511.

22. Mididio L, Brochaño P, Almada M, Duarte M, Paúl C, Costa E. Frailty status and polypharmacy predict all-cause mortality in community dwelling older adults in Europe. Int J Environ Res Public Health 2021;18. doi:10.3390/ijerph18073580.

23. Chen N, Alam AB, Lutsey PL, MacLehose RF, Claxton JS, Chen LY, Chamberlain AM, Alonso A. Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥75 With Atrial Fibrillation. J Am Heart Assoc 2020;9:e015089.

24. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014;13:57–65.

25. Sabhswari SR, Qidwai W, Bhanji S. Polypharmacy in elderly: A cautious trail to tread. J Pak Med Assoc 2013;63:624–627.

26. Lee JY, Kim HA, Huh K, Hyun M, Rhee JY, Jang S, Kim JY, Peck KR, Chang HH. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020;35. doi:10.3346/jkms.2020.35.E223.

27. Berenguer J, Ryan P, Rodríguez-baño J, Jarrín I. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.

28. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, Li Y, Cheng L, Li W, Jia H, Ma X. Epidemiological, comorbidity factors with severity and prognosis. 2020;12:12493–12503.

29. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, Peng Z, Pan H. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhu, China. J Clin Virol 2020;127. doi:10.1016/j.jcv.2020.104364.

30. Waikar SS, Mount DB, Curhan GC. Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia. Am J Med 2009;122:857–865.

31. Bataille S, Barilla C, Torro D, Buffat C, Berland Y, Alazia M, Loundou A, Michelet P, Vacher-Coponat H. Undercorrection of hyponatremia is frequent and associated with mortality. BMC Nephrol 2014;15:1–9.

32. Nair V, Niederman MS, Masani N, Fishbane S. Hyponatremia in community-acquired pneumonia. Am J Nephrol 2007;27:184–190.

33. Ruiz-Sánchez JG, Núñez-Gil II, Cuesta M, et al. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. Front Endocrinol (Lausanne) 2020;11:1–12.

How to cite this article: I. Rodríguez-Sánchez, M. Redondo-Martín, L. Fuentes-Fernández et al. Functional, Clinical, and Sociodemographic Variables Associated with Risk of In-Hospital Mortality by COVID-19 in People over 80 Years Old. J Nutr Health Aging. 2021;25(8):964-970; http://dx.doi.org/10.1007/s12603-021-1664-9